Mutated EGFR-IN-2 |
| Catalog No.GC36667 |
돌연변이 EGFR-IN-2(화합물 91)는 특허 WO2017036263A1에서 추출한 돌연변이 선택적 EGFR 억제제로, 단일 돌연변이 EGFR(T790M) 및 이중 돌연변이 EGFR(L858R/T790M(IC50=<1nM) 및 ex19del 포함)을 강력하게 억제합니다. /T790M), 단일 기능 획득 돌연변이 EGFR(L858R 및 ex19del 포함)의 활성도 억제할 수 있습니다. 돌연변이된 EGFR-IN-2는 항종양 활성을 나타냅니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2050906-97-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Mutated EGFR-IN-2 (compound 91) is a mutant-selective EGFR inhibitor extracted from patent WO2017036263A1, which potently inhibits single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M (IC50=<1nM) and ex19del/T790M), and can suppress activity of single gain-of-function mutant EGFR (including L858R and ex19del) as well. Mutated EGFR-IN-2 shows anti-tumor antivity[1]. EGFRT790M EGFRL858R EGFRex19del EGFR (L858R/T790M)|<1 nM (IC50)|EGFR (ex19del/T790M)
[1]. 2, 4-di-(nitrogen containing group) substituted pyrimidine compound and preparation method and use thereof.
Average Rating: 5 (Based on Reviews and 40 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *